New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Tvardi Therapeutics, Inc.

TVRD

Healthcare Biotechnology

Tvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.

Revenue
+20.3%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

0.99 0.04 +4.21%

After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.

Market cap
$12.6M
P/E
n/m
Fwd P/E FY25e
n/m
Dividend yield
—
F-score
3/9
ROIC
0.00%
Net debt / EBITDA
1.1×
Payout ratio
—

Where the cash went Fiscal 2025, year to Dec 31, 2025

Free cash flow was −$23.5M: capital expenditures were more than operating cash flow. Cash fell by $10.9M. Lines the picture does not name came to +$22.2M. What is a cash flow statement?

Free cash flow
−$23.5M
Returned to shareholders
$0.00
Debt, net
$0.00 borrowed
Change in cash
−$10.9M over the period
Where the cash went, in millions of dollars
Operating cash flow−23.5
Free cash flow−23.5
Into investments, net−10.1
Shares issued, net+0.5
Other+22.2
Change in cash−10.9
Operating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, nine years
FY16FY17FY18FY19FY20FY21FY22FY23FY24
Operating cash flow−$47M−$55M−$22M−$109M−$5.5M−$60M−$79M−$92M−$18M
Capex−$0.7M$0$0.0B$0$0.0B$0$0−$2.4M−$1M
Free cash flow−$48M−$55M−$22M−$109M−$5.8M−$60M−$79M−$94M−$19M

Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Net Income
(18.21) (29.40) (118.51) (85.47) (88.44) 8.41 (106.37) (74.01) (58.12) (57.28)
Depreciation & Amortization
(0.10) 0.10 1.93 1.93 2.42 1.17 (0.58) (1.45) (0.09) 1.25
Non Cash Items (Other)
(5.69) 2.36 14.33 17.73 20.68 14.56 16.57 9.94 6.43 2.66
Accounts Receivable Change
— 1.32 0.44 (3.30) 0.10 0.41 (0.04) (0.80) (0.04) (0.01)
Change in inventories
— (1.04) (0.44) 0.20 (2.58) — — — — —
Change in payables and accrued liability
0.92 5.57 3.28 5.68 (1.02) (2.78) 6.04 5.12 (3.03) 6.27
Income tax paid
— 0.70 — — 0.81 (0.69) (0.15) 0.07 0.12 (0.47)
Change in other assets and liabilities
(0.41) 3.07 7.00 (15.50) 7.96 (26.57) (24.68) 38.84 (0.10) 0.20
Other operating activities
— — (0.11) — — — — — — —
Operating Cash Flow
(23.50) (18.30) (92.08) (78.73) (60.09) (5.49) (109.22) (22.30) (54.83) (47.38)
Capital expenditures
— (1.05) (2.37) (0.04) 0.03 (0.35) (0.02) (0.07) (0.02) (0.72)
Short Term Investments Change (Net)
(10.08) 49.79 45.84 128.75 (4.78) (19.93) (30.50) (82.75) (36.48) 45.74
Investing cash flow
(10.08) 48.74 43.46 128.71 (4.75) (20.27) (30.52) (82.82) (36.50) 45.02
Repayment/Issuance of Debt (Net)
— 28.30 — (1.75) (1.60) (1.09) (0.88) — — —
Equity Repurchase (Common, Net)
0.53 0.01 1.68 0.31 46.61 39.14 142.60 110.81 87.92 0.12
Other financial activities
22.17 (1.30) 36.47 18.00 21.54 (7.54) (4.56) 8.12 5.85 2.45
Financing cash flow
22.70 27.00 38.15 0.31 46.61 39.14 142.60 110.81 87.92 0.12
Change in Cash
(10.88) 8.70 (10.47) 50.29 (18.23) 13.38 2.86 5.69 (3.40) (2.24)
Beginning Cash
31.61 22.92 64.15 13.86 32.09 18.71 15.85 10.16 13.56 15.80
Ending Cash
20.73 31.61 53.68 64.15 13.86 32.09 18.71 15.85 10.16 13.56
Stock Based Compensation
1.40 0.32 13.73 17.73 20.79 14.84 12.57 9.48 5.79 2.80
Dividends Paid (Common)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash/Marketcap
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
0.51 8.64 10.28 (12.92) 5.26 (29.63) (18.84) 43.22 (3.05) 5.99
Investments Change (Net)
(10.08) 49.79 45.84 128.75 (4.78) (19.93) (30.50) (82.75) (36.48) 45.74
Issuance/Purchase of Shares
0.53 0.01 1.68 0.31 46.61 39.14 142.60 110.81 87.92 0.12
Other line items
Revenue per Employee
— 0.71 0.38 0.39 0.27 1.69 0.30 0.24 0.02 0.00

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 17, 2026